567 related articles for article (PubMed ID: 26934120)
21. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
[TBL] [Abstract][Full Text] [Related]
22. [Reversing multidrug resistance in breast cancer cell line MCF-7/ADR by small interfering RNA].
Li CB; Zhang F; Shi YR; Wei XY; Yang Y; Niu RF
Ai Zheng; 2004 Dec; 23(12):1605-10. PubMed ID: 15601546
[TBL] [Abstract][Full Text] [Related]
23. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
24. [Reversal of adriamycin resistance by digoxin in human breast cancer cell line MCF-7/adriamycin and its mechanism].
Li BH; Yuan L; Shi RR; Wang JG
Sheng Li Xue Bao; 2015 Dec; 67(6):611-7. PubMed ID: 26701637
[TBL] [Abstract][Full Text] [Related]
25. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer.
Liu S; Song XL; Wang YH; Wang XM; Xiao Y; Wang X; Cheng L; Li XT
J Drug Target; 2017 Jul; 25(6):541-553. PubMed ID: 28277825
[TBL] [Abstract][Full Text] [Related]
27. Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression.
Zyad A; Bénard J; Tursz T; Clarke R; Chouaib S
Cancer Res; 1994 Feb; 54(3):825-31. PubMed ID: 7905787
[TBL] [Abstract][Full Text] [Related]
28. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
[TBL] [Abstract][Full Text] [Related]
29. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1.
Oh WK; Cho KB; Hien TT; Kim TH; Kim HS; Dao TT; Han HK; Kwon SM; Ahn SG; Yoon JH; Kim TH; Kim YG; Kang KW
Mol Pharmacol; 2010 Nov; 78(5):855-64. PubMed ID: 20713551
[TBL] [Abstract][Full Text] [Related]
30. Combination of 7-
Chen Y; Li X; Shi L; Ma P; Wang W; Wu N; Gan Y; Han X; Huang S; Kang X; Liu S; Zhen Y
Aging (Albany NY); 2022 Sep; 14(17):7156-7169. PubMed ID: 36107024
[TBL] [Abstract][Full Text] [Related]
31. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
Chang L; Hu Z; Zhou Z; Zhang H
Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
[TBL] [Abstract][Full Text] [Related]
32. PRMT2β, a C-terminal splice variant of PRMT2, inhibits the growth of breast cancer cells.
Zhong J; Chen YJ; Chen L; Shen YY; Zhang QH; Yang J; Cao RX; Zu XY; Wen GB
Oncol Rep; 2017 Aug; 38(2):1303-1311. PubMed ID: 28677794
[TBL] [Abstract][Full Text] [Related]
33. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
[TBL] [Abstract][Full Text] [Related]
34. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas.
Hoffmann J; Schmidt-Peter P; Hänsch W; Naundorf H; Bunge A; Becker M; Fichtner I
Clin Cancer Res; 1999 Aug; 5(8):2198-204. PubMed ID: 10473106
[TBL] [Abstract][Full Text] [Related]
35. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance.
Fujita T; Washio K; Takabatake D; Takahashi H; Yoshitomi S; Tsukuda K; Ishibe Y; Ogasawara Y; Doihara H; Shimizu N
Int J Cancer; 2005 Nov; 117(4):670-82. PubMed ID: 15945097
[TBL] [Abstract][Full Text] [Related]
37. Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway.
Zhang ZM; Wu JF; Luo QC; Liu QF; Wu QW; Ye GD; She HQ; Li BA
Oncogene; 2016 Sep; 35(36):4787-97. PubMed ID: 26876203
[TBL] [Abstract][Full Text] [Related]
38. Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1.
Zhao L; Jin X; Xu Y; Guo Y; Liang R; Guo Z; Chen T; Sun Y; Ding X
J Exp Clin Cancer Res; 2010 Jul; 29(1):98. PubMed ID: 20642825
[TBL] [Abstract][Full Text] [Related]
39. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
40. Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
Rigalli JP; Reuter T; Herold-Mende C; Dyckhoff G; Haefeli WE; Weiss J; Theile D
Cancer Chemother Pharmacol; 2013 May; 71(5):1335-43. PubMed ID: 23479137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
